Genaera Corporation to Present at IBC Ocular Anti-Angiogenesis Conference Thursday June 22, 8:30 am ET
PLYMOUTH MEETING, Pa., June 22 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) will present at the First IBC European Ocular Anti-angiogenesis Conference being held June 27-28, 2006 at the Cafe Royale in London, UK. Michael J. Gast, M.D., Ph.D., Senior Vice President, Clinical Research and Development, will present on Tuesday, June 27, 2006 at 5:30 PM GMT. The presentation will highlight recent findings from the Company's Phase II clinical trials with EVIZON(TM) (squalamine lactate) for the treatment of wet age-related macular degeneration (AMD). Squalamine lactate is a first-in- class, anti-angiogenic small molecule being developed for exudative AMD and oncology.
Genaera Corporation is a biopharmaceutical company committed to developing medicines to address substantial unmet medical needs in major pharmaceutical markets. The Company has products in development for the treatment of eye, cancer, respiratory disorders and metabolic syndrome. EVIZON(TM) (squalamine lactate) is Genaera's lead product in development for ophthalmic indications, specifically wet age-related macular degeneration (AMD). Genaera's other programs include: squalamine for the treatment of cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; LOMUCIN(TM), a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease; and trodusquemine (MSI-1436) for the treatment of obesity.
AI
